Table 4.
Clinical characteristics of COVID-19 patients with IL-6 receptor antagonists-associated DILI sourced from the FAERS database (2020q2 to 2021q4)
| Characteristics | Drug report, n (%) | |
|---|---|---|
| TCZ | SAR | |
| Patient age (year) | ||
| 18–44 | 20 (10.42%) | 0 (0.00%) |
| 45–64 | 58 (30.21%) | 3 (3.61%) |
| 65–74 | 21 (10.94%) | 0 (0.00%) |
| 75–84 | 11 (5.73%) | 0 (0.00%) |
| ≥ 85 | 2 (1.04%) | 0 (0.00%) |
| Unknown | 80 (41.67%) | 80 (96.39%) |
| Patient gender | ||
| Female | 25 (13.02%) | 1 (1.20%) |
| Male | 89 (46.35%) | 2 (2.41%) |
| Unknown | 78 (40.63%) | 80 (96.39%) |
| Reporter occupation | ||
| Consumer | 2 (1.04%) | 0 (0.00%) |
| Pharmacist | 52 (27.08%) | 1 (1.20%) |
| Physician | 64 (33.33%) | 82 (98.80%) |
| Unknown | 74 (38.54%) | 0 (0.00%) |
| Report time | ||
| 2020Q2 | 13 (6.77%) | 6 (7.23%) |
| 2020Q3 | 29 (15.10%) | 13 (15.66%) |
| 2020Q4 | 23 (11.98%) | 61 (73.49%) |
| 2021Q1 | 20 (10.42%) | 3 (3.61%) |
| 2021Q2 | 53 (27.60%) | 0 (0.00%) |
| 2021Q3 | 25 (13.02%) | 0 (0.00%) |
| 2021Q4 | 29 (15.10%) | 0 (0.00%) |
| Area | ||
| Africa | 2 (1.04%) | 0 (0.00%) |
| Asian | 22 (11.46%) | 0 (0.00%) |
| Europe | 102 (53.13%) | 13 (15.66%) |
| North America | 53 (27.60%) | 63 (75.90%) |
| South America | 13 (6.77%) | 7 (8.43%) |
| Outcomes | ||
| Congenital anomaly | 0 (0.00%) | 1 (1.22%) |
| Death | 30 (17.14%) | 30 (36.59%) |
| Disability | 1 (0.57%) | 1 (1.22%) |
| Hospitalization initial or prolonged | 27 (15.43%) | 37 (45.12%) |
| Life-threatening | 6 (3.42%) | 29 (35.37%) |
| Other serious (important medical event) | 137 (78.29%) | 54 (65.85%) |
| Required intervention to prevent permanent impairment | 2 (1.14%) | 0 (0.00%) |